Chantale Bernatchez

List of Publications by Year
in descending order

94 papers	9,487 citations	61984 43 h-index	53230 85 g-index
96 all docs	96 docs citations	96 times ranked	15663 citing authors

#	Article	IF	Citations
1	Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy. Cancer Discovery, 2016, 6, 202-216.	9.4	1,158
2	Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell, 2016, 167, 397-404.e9.	28.9	1,009
3	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell, 2018, 175, 984-997.e24.	28.9	892
4	Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metabolism, 2018, 27, 977-987.e4.	16.2	398
5	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature Medicine, 2021, 27, 504-514.	30.7	357
6	Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients. Clinical Cancer Research, 2012, 18, 6758-6770.	7.0	345
7	Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer. JAMA Oncology, 2019, 5, 67.	7.1	344
8	Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. Clinical Cancer Research, 2012, 18, 5329-5340.	7.0	266
9	Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1692-1697.	7.1	237
10	Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. Scientific Reports, 2017, 7, 13380.	3.3	208
11	Identification of bacteria-derived HLA-bound peptides in melanoma. Nature, 2021, 592, 138-143.	27.8	187
12	A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. Cancer Discovery, 2019, 9, 711-721.	9.4	180
13	Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 160-175.	2.0	176
14	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discovery, 2017, 7, 1088-1097.	9.4	160
15	Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). Cancer Discovery, 2020, 10, 1158-1173.	9.4	158
16	Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications, 2020, 11, 603.	12.8	140
17	BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. Cancer Immunology Research, 2015, 3, 602-609.	3.4	133
18	Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. , 2018, 6, 48.		126

#	Article	IF	Citations
19	Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nature Communications, 2020, 11, 661.	12.8	124
20	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. Npj Genomic Medicine, 2017, 2, .	3.8	120
21	RNA editing derived epitopes function as cancer antigens to elicit immune responses. Nature Communications, 2018, 9, 3919.	12.8	120
22	Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. Nature Genetics, 2021, 53, 332-341.	21.4	112
23	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine, 2016, 14, 168.	5.5	106
24	Deep learning-based prediction of the T cell receptor–antigen binding specificity. Nature Machine Intelligence, 2021, 3, 864-875.	16.0	99
25	Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2. Blood, 2003, 102, 2901-2909.	1.4	98
26	Phase 2 study of pembrolizumab in patients with advanced rare cancers. , 2020, 8, e000347.		95
27	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clinical Cancer Research, 2018, 24, 4416-4428.	7.0	89
28	Perturbations in the control of cellular arachidonic acid levels block cell growth and induce apoptosis in HL-60 cells. Carcinogenesis, 1999, 20, 757-763.	2.8	87
29	Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. Cancer Discovery, 2018, 8, 1366-1375.	9.4	80
30	Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers, 2019, 11, 714.	3.7	79
31	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clinical Cancer Research, 2018, 24, 3366-3376.	7.0	73
32	PD-1 and BTLA and CD8^{+}T-cell "exhaustion"in cancer. OncoImmunology, 2012, 1, 735-738.	4.6	71
33	Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nature Communications, 2020, 11, 660.	12.8	68
34	Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. Journal of Hematology and Oncology, 2016, 9, 81.	17.0	62
35	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. Journal of Thoracic Oncology, 2021, 16, 583-600.	1.1	62
36	Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter. Clinical Cancer Research, 2017, 23, 6151-6164.	7.0	58

#	ARTICLE	IF	CITATIONS
37	T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors. Clinical Cancer Research, 2018, 24, 2920-2934.	7.0	58
38	Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies. Cancers, 2020, 12, 255.	3.7	58
39	Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies. Clinical Cancer Research, 2021, 27, 5912-5921.	7.0	57
40	Interaction of low molecular weight group IIA phospholipase A2with apoptotic human T cells: role of heparan sulfate proteoglycans. FASEB Journal, 2003, 17, 1068-1080.	0.5	51
41	BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties. OncoImmunology, 2015, 4, e1014246.	4.6	50
42	A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. , 2016, 4, 55.		50
43	A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes. Frontiers in Immunology, 2017, 8, 908.	4.8	50
44	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. Journal of Thoracic Oncology, 2021, 16, 127-139.	1.1	48
45	Activation and Propagation of Tumor-infiltrating Lymphocytes on Clinical-grade Designer Artificial Antigen-presenting Cells for Adoptive Immunotherapy of Melanoma. Journal of Immunotherapy, 2014, 37, 448-460.	2.4	47
46	Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. Cancer Immunology Research, 2017, 5, 100-105.	3.4	46
47	4-1BB–Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells. Cancer Immunology Research, 2017, 5, 439-445.	3.4	45
48	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. OncoImmunology, 2017, 6, e1321187.	4.6	45
49	Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open, 2018, 3, e000283.	4.5	45
50	4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Clinical Cancer Research, 2017, 23, 7263-7275.	7.0	41
51	Broad Cross-Presentation of the Hematopoietically Derived PR1 Antigen on Solid Tumors Leads to Susceptibility to PR1-Targeted Immunotherapy. Journal of Immunology, 2012, 189, 5476-5484.	0.8	37
52	Advances in the Treatment of Metastatic Melanoma: Adoptive T-Cell Therapy. Seminars in Oncology, 2012, 39, 215-226.	2.2	34
53	SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity. Cancer Immunology Research, 2017, 5, 618-629.	3.4	34
54	Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. , 2020, 8, e000405.		33

#	Article	IF	Citations
55	Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer. PLoS ONE, 2016, 11, e0160004.	2.5	33
56	Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma. Journal of Immunotherapy, 2018, 41, 399-405.	2.4	32
57	Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma. Cancer Discovery, 2021, 11, 1996-2013.	9.4	32
58	Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report. Cancer Immunology Research, 2015, 3, 1201-1206.	3.4	29
59	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clinical Cancer Research, 2021, 27, 3039-3049.	7.0	28
60	Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunology Research, 2017, 5, 319-329.	3.4	25
61	Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue. Scientific Reports, 2021, 11, 8511.	3.3	24
62	Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. , 2021, 9, e002531.		24
63	The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity. OncoImmunology, 2016, 5, e1057386.	4.6	22
64	Absence of Grail promotes CD8+ T cell anti-tumour activity. Nature Communications, 2017, 8, 239.	12.8	22
65	Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. Cancer Discovery, 2022, 12, 2330-2349.	9.4	22
66	A New Approach to Simultaneously Quantify Both TCR α- and β-Chain Diversity after Adoptive Immunotherapy. Clinical Cancer Research, 2012, 18, 4733-4742.	7.0	21
67	Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases. Cancer Immunology Research, 2017, 5, 300-311.	3.4	20
68	Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.. Journal of Clinical Oncology, 2019, 37, 2623-2623.	1.6	20
69	Residues involved in co-factor and substrate binding of the short-chain dehydrogenase/reductase PTR1 producing methotrexate resistance in Leishmania. FEBS Journal, 1998, 251, 768-774.	0.2	18
70	Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. Cancer Immunology, Immunotherapy, 2021, 70, 1101-1113.	4.2	18
71	Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells. Cancer Immunology Research, 2020, 8, 794-805.	3.4	17
72	Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy. Cell Reports, 2021, 36, 109410.	6.4	17

#	Article	IF	Citations
73	Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. Cancer Immunology, Immunotherapy, 2019, 68, 1747-1757.	4.2	16
74	Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. , 2021, 9, e002449.		16
75	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nature Communications, 2020, 11, 1839.	12.8	15
76	Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in <i>KIT</i>-Mutant Melanoma. JCO Precision Oncology, 2018, 2018, 1-8.	3.0	13
77	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clinical Cancer Research, 2021, 27, 5038-5048.	7.0	13
78	Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals. Vaccine, 2011, 29, 3021-3030.	3.8	12
79	Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. , 2022, 10, e003082.		11
80	Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers. Blood Advances, 2021, 5, 2519-2522.	5.2	10
81	Multi-modal molecular programs regulate melanoma cell state. Nature Communications, 2022, 13, .	12.8	9
82	Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. Clinical Cancer Research, 2021, 27, 5062-5071.	7.0	8
83	Identification of MicroRNAâ€"mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers, 2021, 13, 5301.	3.7	7
84	Exposure to antiâ€PDâ€1 causes functional differences in tumorâ€infiltrating lymphocytes in rare solid tumors. European Journal of Immunology, 2019, 49, 2245-2251.	2.9	4
85	OA20.06 Prospective ImmunogenomiC PrOfiling of Non-Small Cell Lung Cancer - The ICON Project. Journal of Thoracic Oncology, 2017, 12, S324-S325.	1.1	3
86	Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clinical Cancer Research, 2022, 28, 1911-1924.	7.0	3
87	Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer, 2020, 146, 303-309.	2.0	2
88	Pulmonary resection for tissue harvest in adoptive tumorâ€infiltrating lymphocyte therapy: Safety and feasibility. Journal of Surgical Oncology, 2021, 124, 699-703.	1.7	2
89	Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. Lung Cancer, 2022, 164, 69-75.	2.0	2
90	P1.05-028 Phenotypic and Functional Profiling of Tumor-Infiltrating Lymphocytes (TIL) in Early Stage Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, S630-S631.	1.1	1

#	Article	IF	Citations
91	Resident Breast T Cells: The Troops Are Already There. Trends in Molecular Medicine, 2018, 24, 821-822.	6.7	1
92	TIL therapy and anti-CTLA4: can they co-exist?. Oncotarget, 2019, 10, 1-2.	1.8	1
93	New epitopes to improve peptide vaccination against the tumorâ€associated antigen Survivin. FASEB Journal, 2008, 22, 526-526.	0.5	0
94	Isolation and Maintenance of Tumor-Infiltrating Lymphocytes for Translational and Clinical Applications: Established Methods and New Developments. Methods in Molecular Biology, 2022, 2435, 43-71.	0.9	0